Technetium (^99mTc) tilmanocept

Technetium (^99mTc) tilmanocept
Clinical data
Trade names	Lymphoseek
AHFS/Drugs.com	lymphoseek
Routes of; administration	Intradermal, subcutaneous
ATC code	V09IA09 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Elimination half-life	1.75 to 3.05 hours at injection site
Identifiers
	IUPAC name Dextran 3-[(2-aminoethyl)thio]propyl 17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D-mannopyranosylthio)ethyl]amino]ethyl]thio]propyl ether technetium-99m complexes;
Chemical and physical data
Formula	(C6H10O5)n(C19H28N4O9S99mTc)3–8(C13H24N2O5S2)12–20(C5H11NS)0–17
Molar mass	15,281–23,454 g/mol

Technetium (^99mTc) tilmanocept, trade name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent approved by the U.S. Food and Drug Administration (FDA) for the imaging of lymph nodes.^[1]^[2] It is used to locate those lymph nodes which may be draining from tumors, and assist doctors in locating those lymph nodes for removal during surgery.^[3]

References

^ ^a ^b FDA Professional Drug Information
^ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm343525.htm
^ Marcinow, A. M.; Hall, N.; Byrum, E.; Teknos, T. N.; Old, M. O.; Agrawal, A. (2013). "Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: Initial institutional report in an ongoing phase 3 study". JAMA Otolaryngology–Head & Neck Surgery. 139 (9): 895–902. doi:10.1001/jamaoto.2013.4239. PMC 4301415. PMID 24051744.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This medical diagnostic article is a stub. You can help Wikipedia by expanding it.

[FDA-Druginfo-1] FDA Professional Drug Information

[2] ttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm343525.htm

[3] Marcinow, A. M.; Hall, N.; Byrum, E.; Teknos, T. N.; Old, M. O.; Agrawal, A. (2013). "Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: Initial institutional report in an ongoing phase 3 study". JAMA Otolaryngology–Head & Neck Surgery. 139 (9): 895–902. doi:10.1001/jamaoto.2013.4239. PMC 4301415. PMID 24051744.

[1]

[2]

[3]